NeOnc's NEO100 Phase 2a 6-month progression-free survival rate about 2.5x historical benchmark

NTHI NeOnc Technologies Holdings Inc

$2.77 +1.84%

View chart & analysis →

1. 1NeOnc Technologies Holdings (NTHI) announced encouraging Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma
2. 26-month progression-free survival rate of 48.9% is roughly 2.5x the historical benchmark of 20%, with statistical significance at p=0.0047
3. 3Study enrolled 24 patients who relapsed after standard treatment, with plans to discuss a large-scale registrational trial pathway with the FDA

Source Newsfile +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →